Can I buy colistin without a prescription in the EU?

No. Colistin is prescription-only in all EU member states. It requires a physician's authorisation, typically from an infectious disease specialist or hospital. This legal restriction ensures safe, appropriate use in serious infections only.

Is colistin banned in any EU country?

Colistin is not banned in any EU member state. It's EMA-authorised, meaning it's legal throughout the EU. However, national regulations and hospital policies may restrict when and how it's prescribed, consistent with antibiotic stewardship principles.

What makes colistin legal despite its side effects?

Colistin's nephrotoxicity and neurotoxicity risks are outweighed by its benefit in treating life-threatening multidrug-resistant infections where alternatives have failed. The EMA's approval reflects this benefit-risk balance, and strict monitoring requirements mitigate harm. It's a last-resort therapy, legally reserved for critical situations.

Do I need special authorisation to prescribe colistin in the EU?

Requirements vary by country and hospital. Some EU nations require infectious disease specialist approval; others follow hospital antimicrobial stewardship protocols. All require a valid prescription and documented clinical justification. Check your national health authority's guidelines.

Is veterinary colistin use legal in the EU?

Colistin is approved for veterinary use in the EU but with increasing restrictions. The EU has banned colistin as a growth promoter and is phasing out its use in animal agriculture to combat antibiotic resistance. Therapeutic veterinary use remains regulated separately from human medicine.

Is Colistin Legal in the EU? Status & Regulations

Yes, colistin is legal in the EU. It's an EMA-authorised antibiotic used to treat serious, life-threatening bacterial infections caused by multidrug-resistant gram-negative bacteria. Colistin was approved by the European Medicines Agency and is available as a prescription-only medicine in EU member states. However, its use is strictly controlled due to nephrotoxicity (kidney damage) and neurotoxicity risks, and it's reserved for infections where other antibiotics have failed or are ineffective. The regulatory landscape reflects colistin's critical role as a last-resort therapy rather than a first-line treatment.

Legal Status in the EU

Colistin holds EMA authorisation across the European Union, making it a legally available pharmaceutical. This approval means it's manufactured, distributed, and prescribed under strict regulatory oversight in all EU member states. The medicine is listed in national formularies and reimbursement schemes, though access varies by country based on local health authority guidelines.

The EMA's approval reflects decades of clinical experience. Colistin has been used clinically since the 1950s, and modern formulations benefit from extensive safety and efficacy data. Over 119 clinical trials have evaluated colistin's use across different infection types and patient populations.

Why Colistin Remains Restricted

Legal doesn't mean unrestricted. Colistin's regulatory status in the EU comes with significant guardrails:

Indication Specificity

Colistin is approved specifically for treating serious infections caused by aerobic gram-negative bacteria resistant to other antibiotics. This includes Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae. It's not licensed for minor infections or preventive use.

Prescription-Only Status

Colistin requires a doctor's prescription in all EU countries. You cannot buy it over-the-counter, and pharmacists cannot dispense it without medical authorisation. This legal barrier protects patients from self-administration and helps prevent antibiotic resistance.

Safety Monitoring Requirements

EU-approved colistin products include detailed safety labelling addressing nephrotoxicity and neurotoxicity risks. Prescribers must monitor kidney function (creatinine clearance) before, during, and after treatment. These aren't suggestions—they're regulatory requirements embedded in the product information for all colistin medicines.

Regulatory Context: Colistin vs. Colistin Sulphate

Two forms exist:

Colistin sulphate (polymyxin E sulphate): The intravenous formulation approved for systemic infections. This is the primary EMA-authorised product.
Colistin methanesulphonate sodium (CMS): A prodrug that converts to colistin in the body; also EMA-approved and widely used.

Both are legal; both require prescriptions; both are reserved for serious, resistant infections.

Antibiotic Stewardship & Regulatory Boundaries

The EU's legal framework for colistin is intertwined with antibiotic stewardship. The European Commission and EMA actively promote responsible antibiotic use to slow resistance. Colistin's legal use is therefore conditional on demonstrating that other treatments have failed.

Many EU hospitals operate colistin formularies or require infectious disease specialist approval before prescribing. These aren't legal prohibitions—they're clinical governance policies aligned with regulatory intent.

Clinical Evidence Supporting Legal Approval

Colistin's legal status rests on substantial clinical evidence. Studies demonstrate efficacy against multidrug-resistant gram-negative infections, particularly in critical care settings. The benefit-risk profile—serious infections where alternatives don't work versus known nephrotoxicity—justifies its legal availability under medical supervision.

Comparison with Other Jurisdictions

Colistin's legal standing in the EU aligns with approvals elsewhere:

United States: FDA-approved for intravenous use in serious infections caused by susceptible organisms.
Canada: Health Canada has authorised colistin for similar indications.

This global regulatory consensus supports the legal and clinical rationale for colistin's availability.

Accessing Colistin Legally in the EU

If you need colistin:

Consult a physician with expertise in serious bacterial infections (typically infectious disease specialists or intensivists).
Undergo diagnostic testing to confirm a multidrug-resistant gram-negative infection and to rule out treatable alternatives.
Receive a prescription based on the approved indications and dosing guidelines in the product information.
Expect monitoring: Kidney function tests and clinical assessment are standard during colistin therapy.

The legal process is deliberately structured to ensure colistin reaches patients who need it while minimising harm and resistance.

Regulatory Transparency

All EMA-approved colistin medicines have publicly available product information and assessment reports. The EMA's website hosts summaries of product characteristics (SmPC) and EU assessment reports for transparency. This regulatory openness is a hallmark of EU pharmaceutical governance.

Related Compounds & Further Reading

If you're researching antibiotic options, explore polymyxin B, another last-resort agent with similar regulatory status, and tigecycline, a broad-spectrum antibiotic approved for resistant infections. Understanding the antibiotic resistance landscape helps contextualise why colistin remains legally available and strategically important.